Top Markets
Coin of the day
Invivyd, Inc. Invivyd, Inc.

Invivyd, Inc.

IVVD
Rank in Stocks #17261
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development... Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Share Price
$0.8502
Last synced: 2026-09-01
Market Cap
$250.47M
Change (1 day)
-10.96%
Change (1 year)
-17.46%
Country
US
Trade Invivyd, Inc. (IVVD)

Category

P/S ratio for Invivyd, Inc. (IVVD)
P/S ratio as of 2026 TTM: 0
According to Invivyd, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Invivyd, Inc. from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
10.95 -
US
12.19 -
NL
24.99 -
US
3.75 -
AU
- -
CH